Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "biologics"

747 News Found

JP Nadda highlights India’s push for APIs, biologics and translational research
Policy | May 01, 2026

JP Nadda highlights India’s push for APIs, biologics and translational research

On his visit to NIPER Mohali, union health minister vreviews biopharma research initiatives and calls for stronger industry collaboration and commercialization focus


Betting on NK-cell innovation and combination immunotherapy to build global clinical-stage biotech: Dr Maloy Ghosh, CSO, Zumutor Biologics
interviews | April 29, 2026

Betting on NK-cell innovation and combination immunotherapy to build global clinical-stage biotech: Dr Maloy Ghosh, CSO, Zumutor Biologics

Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies


Aurobindo’s TheraNym to invest up to $175 million in expanded biologics deal with MSD
Biopharma | April 16, 2026

Aurobindo’s TheraNym to invest up to $175 million in expanded biologics deal with MSD

TheraNym will set up a greenfield large-scale mammalian drug substance manufacturing facility


Samsung Biologics lands first US manufacturing facility with GSK acquisition
News | April 06, 2026

Samsung Biologics lands first US manufacturing facility with GSK acquisition

Samsung Biologics will continue supplying products previously manufactured at the site to GSK


Biocon renames Irish step-down subsidiary as Biocon Biologics Ireland
Biotech | April 06, 2026

Biocon renames Irish step-down subsidiary as Biocon Biologics Ireland

Move aligns global biologics identity under the Biocon Biologics brand


Innovent Biologics’ OLN324 shows breakthrough results in vision disease study
Biopharma | April 05, 2026

Innovent Biologics’ OLN324 shows breakthrough results in vision disease study

The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred


Samsung Biologics scores big at 2026 CDMO Leadership Awards
News | March 31, 2026

Samsung Biologics scores big at 2026 CDMO Leadership Awards

The CDMO Leadership Awards spotlight top-performing development and manufacturing service providers


CuraTeQ Biologics enters into agreement with STADA Arzneimittel AG
News | March 27, 2026

CuraTeQ Biologics enters into agreement with STADA Arzneimittel AG

STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories


Earendil Labs bags $787m to supercharge AI-driven biologics pipeline
Biotech | March 25, 2026

Earendil Labs bags $787m to supercharge AI-driven biologics pipeline

Capital infusion to accelerate Earendil’s R&D platform


Samsung Biologics, Eli Lilly team up to launch major biotech hub in Korea
R&D | March 17, 2026

Samsung Biologics, Eli Lilly team up to launch major biotech hub in Korea

The planned facility, to be built at Samsung’s Bio Campus II, is set to become a launchpad for up to 30 emerging biotech firms